Health Care & Life Sciences » Pharmaceuticals | Peptron Inc.

Peptron Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
3,103
2,484
2,812
3,131
3,215
Cost of Goods Sold (COGS) incl. D&A
1,832
1,451
2,006
2,027
2,134
Gross Income
1,272
1,032
806
1,104
1,081
SG&A Expense
3,129
3,614
3,656
4,668
5,855
EBIT
1,941
2,609
2,850
3,564
4,774
Unusual Expense
504
55
88
116
170
Non Operating Income/Expense
120
34
37
19
42
Interest Expense
762
590
92
69
-
Pretax Income
2,058
3,069
2,765
3,096
4,473
Income Tax
1
23
34
95
46
Consolidated Net Income
2,059
3,046
2,730
3,191
4,427
Net Income
2,059
3,046
2,730
3,191
4,427
Net Income After Extraordinaries
2,059
3,046
2,730
3,191
4,427
Net Income Available to Common
2,059
3,046
2,730
3,191
4,427
EPS (Basic)
316.83
468.66
225.77
218.69
291.50
Basic Shares Outstanding
13
13
12
15
15
EPS (Diluted)
158.42
234.33
225.77
218.69
291.56
Diluted Shares Outstanding
13
13
12
15
15
EBITDA
1,378
2,031
2,252
2,962
4,180
Other Operating Expense
83
28
-
-
-
Non-Operating Interest Income
21
42
53
403
514

About Peptron

View Profile
Address
37-24 Yuseong-daero 1628beon-gil
Daejeon DE 34054
Korea, Republic Of
Employees -
Website http://www.peptron.co.kr
Updated 09/14/2018
Peptron, Inc. engages in the development of peptide-based medicines and novel drugs. Its products include medicines for prostate cancer, hyperpituitarism, diabetes, degenerative neuronal disease, and obesity, peptide materials, and cosmetics. The company was founded on November 21, 1997 and is headquartered in Daejeon, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.